

Listing of 2018 NCIP/VFC Vaccines

The table below lists NCIP/VFC vaccines provided in North Carolina to VFC eligible children ages 18 years and younger.

Code	CPT Description	VFC Vaccine Specifics
90633	Hepatitis A vaccine, pediatric/adolescent dosage – 2 dose schedule, for IM use	12 months of age through 18 years of age
90636	Hepatitis A and B combination (HepA-HepB), adult dosage, for IM use	18 years of age and above only in LHDs, FQHCs, and RHCs
90647	Hemophilus influenza type b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), for IM use	Brand name: PedvaxHIB Routine: 2 months to less than 5 years of age; High risk: Greater than 59 months through 18 years of age
90648	Hemophilus influenza type b vaccine (Hib), PRP-T conjugate (4 dose schedule), for IM use	Brand name: ActHIB, Hiberix Routine: 2 months to less than 5 years of age High risk- greater than 59 months through 18 years of age
90651	Human papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV)	Brand name: Gardasil 9 Females and Males 9 through 18 years of age
90686	Influenza virus vaccine, quadrivalent split virus, preservative free, for IM use	3 through 18 years of age
90687	Influenza virus vaccine, quadrivalent, split virus, for IM use	6-35 months of age
90688	Influenza virus vaccine, quadrivalent, split virus, for IM use	3 through 18 years of age
90674	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for IM	4 through 18 years of age ** available after 10/15/16
90670	Pneumococcal conjugate vaccine, 13 valent, for IM use	Brand name: Prevnar 13 Routine: 2 months through 59 months of age High Risk: 60 months through 18 years of age with certain underlying medical conditions
90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use	Brand name: Rotateq 6 weeks through 7 months of age
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Brand name: Rotarix 6 weeks through 7 months of age
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), for IM use	4 years through 6 years of age for the booster dose only of DTaP and polio vaccines
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenza type b, and poliovirus vaccine, inactivated (DTaP-IPV/Hib), for IM use	2 months through 4 years of age
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), for IM use	2 months through 6 years of age
90702	Diphtheria and tetanus toxoids adsorbed (DT), for IM use	2 months through 6 years of age
90707*	Measles, mumps, and rubella virus vaccine (MMR), live, for SC use	12 months through 18 years of age*
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for SC use	12 months through 12 years of age

Code	CPT Description	VFC Vaccine Specifics
90713	Poliovirus vaccine, inactivated (IPV), for SC or IM use	2 months through 17 years of age
90714*	Tetanus and diphtheria, adsorbed	7 years through 18 years of age*
90715*	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for IM use	7 years through 18 years of age*
90716	Varicella virus vaccine, live, for SC use	12 months through 18 years of age
90723	Diphtheria, tetanus toxoids, and acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, (Dtap-HepB-IPV), for IM use	2 months through 6 years of age
90732	Pneumococcal polysaccharide vaccine, 23-valent, (PPSV23) adult or immunosuppressed patient dosage, for SC or IM use	Only for high-risk children two years through 18 years of age
90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 tetravalent NCV4 or MenACWY, for IM use	Routine: 11 through 18 years of age High risk: 2 months through 10 years Menveo- starts at 2 months of age Menactra- starts at 9 months of age
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB), 2 dose schedule, for IM use	Brand name: Bexsero High risk children ages 10-18 MenB may be administered to adolescents aged 16–18 years of age who are not at increased risk for meningococcal disease based on the provider's clinical discretion. Follow ACIP guidance.
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB), 3 dose schedule, for IM use	Brand name - Trumenba High risk children ages 10-18 Children aged 16-18 years without high risk conditions may also be vaccinated based on the providers clinical judgement for children who are at increased risk for disease.
90744	Hepatitis B vaccine pediatric/adolescent dosage (3 dose schedule), for IM use	Birth through 19 years of age
90746	Hepatitis B vaccine, adult dosage, for IM use, 3 dose schedule	20 years of age and older, only in LHDs